Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human … – OrthoSpineNews

FREDERICK, Md.,May 22, 2024/PRNewswire/ Theradaptive, Inc., a regenerative medicine company developing targeted therapeutics, announced today it has been awarded funding from the Maryland Stem Cell Research Fund (MSCRF) to support human clinical trials for its lead product, OsteoAdapt SP. OsteoAdapt SP is currently in Phase I/II clinical studies for transforaminal lumbar interbody spinal fusion (TLIF) to treat degenerative disc disease, spondylolisthesis, and retrolisthesis.

Theradaptive was granted an Investigational Device Exemption (IDE) inJanuary 2024by the U.S. Food and Drug Administration (FDA) to begin its human clinical trial. This$1 millionaward from the MSCRF Clinical Program will enable Theradaptive to expand its OASIS human clinical study to sites inMaryland. More details can be found at ClinicalTrials.gov: identifierNCT06154005. Theradaptive also holds three Breakthrough Medical Device designations for various spine indications including TLIF, ALIF, and PLF.

We are so grateful to the Maryland Stem Cell Research Fund for this generous support as we take OsteoAdapt SP through clinical development,saidLuis Alvarez, PhD, CEO and Founder of Theradaptive. This grant will expand our ability to provide patients with limited options a much better alternative by accelerating the development of this ground-breaking technology.

How OsteoAdapt SP is changing biologic implants

OsteoAdapt SP is a biologic-enhanced implant designed to stimulate anatomically precise local bone growth and promote rapid fusion following spinal surgery. It combines a proprietary protein called AMP2 that activates a patients own stem cells with a resorbable scaffold implant. This implant remodels into bone and completely resorbs, leaving no trace behind. This technology ushers in the next generation of regenerative therapeutics compared to the current standard of care by mitigating side effects and significantly improving safety and efficacy over traditional bone grafts and biologics.

This funding will benefit us greatly as we work toward making this revolutionary therapy available to patients in need, puttingMarylandat the forefront of innovation in regenerative bone repairsaidJonathan Elsner, PhD, Vice President of Clinical Operations. We appreciate that MSCRF recognizes the importance of this program and look forward to dosing the first patient in the coming months.

Our goal is to accelerate the development of promising technologies by providing funding to help them reach patients as quickly as possible,said Ruchika Nijhara, Executive Director of MSCRF.We are enthusiastic about the potential of OsteoAdapt SP to benefit patients suffering from debilitating spine conditions.

Theradaptive was spun out of theMassachusetts Institute of Technologyin 2017 to commercialize a platform that immobilizes therapeutic proteins on implantable biomaterials. The companys near-term focus is on regenerative treatments for musculoskeletal conditions and spinal fusion surgery.

Clinical sites investigating OsteoAdapt SP in TLIF procedures are currently enrolling patients across the U.S., includingMaryland, and inAustralia.

Theradaptive plans to file for marketing authorization with the U.S. Food and Drug Administration following successful completion of pivotal clinical studies.

About Theradaptive

Theradaptive, Inc. is a privately held regenerative medicine company developing therapeutic implants that harness the bodys own stem cells to regenerate tissues. The companys proprietary AMP2 technology platform enables localized, sustained delivery of therapeutic proteins to trigger highly targeted regenerative responses.

Theradaptives lead clinical program, OsteoAdapt SP, is an investigational bone graft material designed to improve spinal fusion outcomes. For more information, visitwww.theradaptive.com.

Contact:Harry Warne Senior Contributor Flame PR Harry@flamepr.com

SOURCE Theradaptive

See the rest here:
Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human ... - OrthoSpineNews

Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine’s Potential – Intelligent Living

We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalised ads. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Originally posted here:
Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine's Potential - Intelligent Living

Using stem cell-derived heart muscle cells to advance heart regenerative therapy – Anti Aging News

198 0 Posted on Apr 29, 2024, 12 p.m.

Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. However, the risk of arrhythmias following this procedure is reportedly high. In a recent study, researchers from Japan tested a novel approach that involves injecting 'cardiac spheroids,' cultured from human stem cells, directly into damaged ventricles. The highly positive outcomes observed in primate models highlight the potential of this strategy.

Cardiovascular diseases are still among the top causes of death worldwide, and especially prevalent in developed countries. Myocardial infarctions, commonly known as "heart attacks," are on the rise, resulting in a significant number of deaths each year.

Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state. Since mammals cannot regenerate cardiac muscle cells on their own, heart transplants are currently the only clinically viable option for patients suffering (or likely to suffer) heart failure. Given that full heart transplants are expensive and donors difficult to come by, it is no surprise that alternative therapies are highly sought after by the medical community.

One promising strategy that has been steadily gaining traction is using human induced pluripotent stem cells (HiPSCs) for regenerative heart therapy. Simply put, HiPSCs are cells derived from mature cells that can be effectively 'reprogrammed' into a completely different cell type, such as cardiac muscle cells (cardiomyocytes). By transplanting or injecting cardiomyocytes derived from HiPSCs into damaged areas of the heart, it is possible to recover some lost functionality. Unfortunately, studies have reported that this approach can increase the risk of arrythmias, posing a major hurdle to clinical trials.

In a recent study, a Japanese research team from Shinshu University and Keio University School of Medicine, tested a new strategy for regenerative heart therapy that involves injecting 'cardiac spheroids' derived from HiPSCs into monkeys with myocardial infarction. This study, published on April 26, 2024, in the journal Circulation, was led by Professor Yuji Shiba from the Department of Regenerative Science and Medicine, Shinshu University.

The team included Hideki Kobayashi, the first author, and Koichiro Kuwahara from the Department of Cardiovascular Medicine, Shinshu University School of Medicine, as well as Shugo Tohyama, and Keiichi Fukuda from the Department of Cardiology, Keio University School of Medicine, among others.

In their novel approach, the researchers cultivated HiPSCs in a medium that led to their differentiation into cardiomyocytes. After carefully extracting and purifying cardiac spheroids (three-dimensional clusters of cardiac cells) from the cultures, they injected approximately 6 107 cells into the damaged hearts of crab-eating macaques (Macaca fascicularis). They monitored the condition of the animals for twelve weeks, taking regular measurements of cardiac function. Following this, they analyzed the monkeys' hearts at the tissue level to assess whether cardiac spheroids could regenerate the damaged heart muscles.

First, the team verified the correct reprogramming of HiPSCs into cardiomyocytes. They observed, via cellular-level electrical measurements, that the cultured cells exhibited potential patterns typical of ventricular cells. The cells also responded as expected to various known drugs. Most importantly, they found that the cells abundantly expressed adhesive proteins such as connexin 43 and N-cadherin, which would promote their vascular integration into an existing heart.

Afterwards, the cells were transported from the production facility at Keio University to Shinshu University, located 230 km away. The cardiac spheroids, which were preserved at 4 C in standard containers, withstood the four-hour journey without problem. This means that no extreme cryogenic measures would be needed when transporting the cells to clinics, which would make the proposed approach less expensive and easier to adopt.

Finally, the monkeys received injections of either cardiac spheroids or a placebo directly into the damaged heart ventricle. During the observation period, the researchers noted that arrythmias were very uncommon, with only two individuals experiencing transient tachycardia (fast pulse) in the first two weeks among the treatment group. Through echocardiography and computed tomography exams, the team confirmed that the hearts of monkeys that received treatment had better left ventricular ejection after four weeks compared to the control group, indicating a superior blood pumping capability.

Histological analysis ultimately revealed that the cardiac grafts were mature and properly connected to pre-existing existing tissue, cementing the results of previous observations. "HiPSC-derived cardiac spheroids could potentially serve as an optimal form of cardiomyocyte products for heart regeneration, given their straightforward generation process and effectiveness," remarks Assistant Professor Kobayashi. "We believe that the results of this research will help solve the major issue of ventricular arrhythmia that occurs after cell transplantation and will greatly accelerate the realization of cardiac regenerative therapy," he further adds.

Although tested in monkeys, it is worth noting that the cardiac spheroid production protocol used in this study was designed for clinical application in humans. "The favorable results obtained thus far are sufficient to provide a green light for our clinical trial, called the LAPiS trial. We are already employing the same cardiac spheroids on patients with ischemic cardiomyopathy," comments Asst. Prof. Kobayashi.

Let us all hope for a resounding success in the LAPiS trial, paving the way for expanded and effective treatment avenues for people suffering from heart problems.

Link:
Using stem cell-derived heart muscle cells to advance heart regenerative therapy - Anti Aging News

3D Cell Culture Market is expected to reach revenue of USD 5.0 Bn by 2032, at 12.0% CAGR: Insights by Dimension … – GlobeNewswire

New Jersey, New York, Los Angeles, Austin, San Diego, Philadelphia, Phoenix, April 23, 2024 (GLOBE NEWSWIRE) -- Overview

The 3D Cell Culture Market size was valued at USD 1.8 billion in 2023 and is further anticipated to reach USD 5.0 billion by 2032 at a CAGR of 12.0% from 2024 to 2032.

The 3D Cell Culture Market involves developing and manufacturing services related to cultivating cells in a three-dimensional environment, which is crucial for pharmaceutical and biotech industries. These cultures mimic natural cellular environments, aiding research on cell behavior, cancer studies, tissue engineering, and drug testing. The market supplies products, equipment, and tissue engineering services.

Important Insights

Elevate Your Strategy with Our Exclusive Report: Request Your Sample Now at: https://dimensionmarketresearch.com/report/3d-cell-culture-market/request-sample/

Latest Trends

3D Cell Culture Market: Competitive Landscape

Some of the prominent market players:

Transform your business approach with strategic insights from our report. Get in touch to request our brochure today:

https://dimensionmarketresearch.com/report/3d-cell-culture-market/download-reports-excerpt/

3D Cell Culture Market Scope

Market Analysis

Scaffold-based technology is projected to dominate the 3D cell culture market with 49.3% of market share in 2023. It naturally is able to replicate extracellular matrices of different cells assisting in tissue engineering and regenerative medicine. Advances in this area are conduits created by 3D-printed edible scaffolds. There are other techniques, like scaffold-free, bioreactors, microfluidics, and bio-printing, that are suitable in that context, depending on the research objectives.

Biotechnology and pharmaceutical companies dominate the 3D cell culture market, holding 48.0% in 2023 with expected growth. 3D cell culture is the preferred direction for the drug development process, because it allows for more accurate identification of candidates, further safety and efficiency analysis, and low-cost drug screening, thus encouraging market development.

Growth Drivers

Restraints

Growth Opportunities

Drive Your Business Growth Strategy: Purchase the Report for Key Insights at: https://dimensionmarketresearch.com/checkout/3d-cell-culture-market/

3D Cell CultureMarket Segmentation

By Technology

By Application

By End-User

Elevate Your Strategy with Our Exclusive Report: Request Your Sample Now at: https://dimensionmarketresearch.com/report/3d-cell-culture-market/request-sample/

Regional Analysis

North America accounts for the biggest share in the 3D cell culture market with a 3D cell culture market share of 46.9% in 2023. North America is expected to be the largest player in the 3D cell culture market due to its advanced manufacturing sector which is predominantly developed and well funded by the effective pharmaceutical and biotechnology industries. Firstly, the advanced and demanding regulations prevailing in this region, especially considering the FDA's promptness in responding to innovative and modern testing techniques, promote a very different environment that is uniquely suitable for medical research, innovation, and technological advancements.

By Region

North America

Europe

Asia-Pacific

Latin America

Middle East & Africa

Discover additional reports tailored to your industry needs

Recent Developments in the 3D Cell Culture Market

About Dimension Market Research (DMR):

Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world. We also believe that our clients dont always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.

More here:
3D Cell Culture Market is expected to reach revenue of USD 5.0 Bn by 2032, at 12.0% CAGR: Insights by Dimension ... - GlobeNewswire

New Stem Cell Research Offers First Glimpse of Early Human Development – SciTechDaily

Using a novel stem cell model, scientists have advanced our understanding of gastrulationa critical early stage of human developmentoffering new insights that could improve outcomes in pregnancy and the understanding of developmental disorders. The image above shows a blastoid, a stem cell model system that allows scientists to study the nuances of human gastrulation. Credit: Laboratory of Stem Cell Biology and Molecular Embryology at The Rockefeller University

Its one of lifes most defining momentsthat crucial step in embryonic development, when an indistinct ball of cells rearranges itself into the orderly three-layered structure that sets the stage for all to come. Known as gastrulation, this crucial process unfolds in the third week of human development. Gastrulation is the origin of our own individualization, the emergence of our axis, says Rockefellers Ali Brivanlou. It is the first moment that separates our heads from our behinds.

Observing the molecular underpinnings of this pivotal event would go a long way toward helping scientists prevent miscarriages and developmental disorders. But studying human gastrulation has proven both technologically difficult and ethically complicated, and thus current approaches have had limited success in expanding our understanding of early human development. Now Brivanlou and colleagues have demonstrated how a stem cell model system known as a blastoid can allow the study of the nuances of human gastrulation in the presence of pre-implantation extra-embryonic cell types. Their study, published in Stem Cell Reports, describes the scientific and clinical potential of this new platform.

Gastrulation was a tremendous black box. We had never seen ourselves at that stage, Brivanlou says. This moves us closer to understanding how we begin.

Prior to implantation, an embryo is a ball of about 250 cells organized as a blastocyst. This elusive ball of cells was difficult to study directly, so scientists developed blastoidsstem-cell-based blastocyst models. Blastoids can be cloned, experimentally manipulated, and programmed, allowing scientists to study identical blastoids over and over again.

The question was whether blastoids could gastrulate in vitro. Unlike a blastocyst in vivo, which rolls around in the uterus until it attaches to maternal tissue, blastoids were good at modeling the ball of cells from which life emerges, but it remained unclear whether this in vitro model could model later stages of human development. That is, until Brivanlou developed a platform to allow blastoids to attach in vitro, and thereby progress toward gastrulation.

We were then able to see epiblast symmetry breaking, marked by BRA expression, for the first time with the high molecular resolution, says Riccardo De Santis, a research associate in the Brivanlou lab and lead author on the study. This allowed us to start asking more detailed questions about the earliest moments of life.

With this unprecedented clarity, the team directly observed two key moments in gastrulation: the first epiblast symmetry-breaking event and the emergence of the molecular markers of the primitive streak and mesoderm upon in vitro attachment.

The primitive streak is a structure that marks the beginning of gastrulation and lays the foundation for the three primary layers of the embryo. One of those layers, the mesoderm, forms during gastrulation and gives rise to muscles, bones, and the circulatory system. The team discovered that, as early as seven days after attachment, they were already able to use molecular markers to detect the earliest signature of a nascent primitive streak and mesodermal cells.

To confirm their findings, the team also compared the blastoid results with data from in vitro attached human embryos and demonstrated that blastoids express the same genes in vitro that a regular embryo would at that stage in vivo, a strong demonstration of the power of blastoids as models for human embryonic development. Further highlighting the power of the labs in vitro attached blastoid system, the team then used it to demonstrate that pathways that regulate the rise of the primitive streak and mesoderm in vivo also regulate blastoids symmetry breaking in vitroall with nothing but stem-cell-derived blastoid models.

Along the way, the team also demonstrated that gastrulation in vitro can begin at day 12, earlier than once thought. This will change textbooks, Brivanlou says. Weve contributed to redefining the molecular signature and timing of the onset of gastrulation upon in vitro attachment.

The results demonstrate that blastoids, when combined with the Brivanlou labs unique attachment platform, are now capable of conveying insights into early human development that have long been inaccessible. De Santis envisions a future in which blastoid-based research leads to advancements in diagnosing and treating developmental disorders, or offers insights into potential causes of early miscarriages during gastrulation.

Many couples cant have babies because the embryo doesnt attach properly, and many miscarriages occur in the first few weeks of pregnancy, De Santis explains. We now have a model system that can help us understand the molecular mechanism that defines whether a pregnancy will be successful or not. In the near future, De Santis hopes to combine this method with machine learning to help predict pregnancy outcomes and the trajectories of developmental disorders by observing how model blastoids built with particular genetic makeups fare in vitro.

A better understanding of gastrulationand the ability to study it with a reliable model systemimpacts everything from survival of the fetus to autism to neurodegeneration.

Reference: The emergence of human gastrulation upon in vitro attachment by Riccardo De Santis, Eleni Rice, Gist Croft, Min Yang, Edwin A. Rosado-Olivieri and Ali H. Brivanlou, 14 December 2023, Stem Cell Reports. DOI: 10.1016/j.stemcr.2023.11.005

Visit link:
New Stem Cell Research Offers First Glimpse of Early Human Development - SciTechDaily

Vitamin A’s Puzzling Effects Unraveled: New Research Sheds Light on Stem Cell Repair Mechanisms – SciTechDaily

Hair follicle stem cells (green) mobilize and expand (white) to help repair the skins barrier by differentiating into epidermal lineages (red). Credit: Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development at The Rockefeller University

When a child falls off her bike and scrapes her knee, skin stem cells rush to the rescue, growing new epidermis to cover the wound. However, only a portion of these stem cells, which eventually repair the damage, are typically assigned the task of replenishing the epidermis that protects her body.

Others are former hair follicle stem cells, which usually promote hair growth but respond to the more urgent needs of the moment, morphing into epidermal stem cells to bolster local ranks and repair efforts. To do that, these hair follicle stem cells first enter a pliable state in which they temporarily express the transcription factors of both types of stem cells, hair, and epidermis.

Now, new research demonstrates that once stem cells have entered this state, known as lineage plasticity, they cannot function effectively in either role until they choose a definitive fate. In a screen to identify key regulators of this process, retinoic acid, the biologically active form of Vitamin A, surfaced as a surprising rheostat. The findings shed light on lineage plasticity, with potential clinical implications.

Our goal was to understand this state well enough to learn how to dial it up or down, says Rockefellers Elaine Fuchs. We now have a better understanding of skin and hair disorders, as well as a path toward preventing lineage plasticity from contributing to tumor growth.

Lineage plasticity has been observed in multiple tissues as a natural response to wounding and an unnatural feature of cancer. But minor skin injuries are the best place to study the phenomenon, because the skins outer layers are subject to perpetual abuse. And when the scratches or abrasions damage the epidermis, hair follicle stem cells are the first responders.

Fuchs and colleagues began to look more closely at lineage plasticity because it, can act as a double-edged sword, explains Matthew Tierney, lead author on the paper and an NIH K99 pathway to independence postdoctoral awardee in the Fuchs lab. The process is necessary to redirect stem cells to parts of the tissue most in need but, if left unchecked, it can leave those same tissues vulnerable to chronic states of repair and even some types of cancer.

To better understand how the body regulates this process, Fuchs and her team screened small molecules for their ability to resolve lineage plasticity in cultured mouse hair follicle stem cells, under conditions that mimicked a wound state. They were surprised to find that retinoic acid, a biologically active form of vitamin A, was essential for these stem cells to exit lineage plasticity and then be coaxed to differentiate into hair cells or epidermal cells in vitro.

Through our studies, first in vitro and then in vivo, we discovered a previously unknown function for vitamin A, a molecule that has long been known to have potent but often puzzling effects on skin and many other organs, Fuchs says. The team found that genetic, dietary, and topical interventions that boosted or removed retinoic acid from mice all confirmed its role in balancing how stem cells respond to skin injuries and hair regrowth. Interestingly, retinoids did not operate on their own: their interplay with signaling molecules such as BMP and WNT influenced whether the stem cells should maintain quiescence or actively engage in regrowing hair.

The nuance did not stop there. Fuchs and colleagues also demonstrated that retinoic acid levels must fall for hair follicle stem cells to participate in wound repairif levels are too high, they fail to enter lineage plasticity and cant repair woundsbut if the levels are too low, the stem cells focus too heavily on wound repair, to the expense of hair regeneration.

This may be why vitamin As effects on tissue biology have been so elusive, Fuchs says.

One result of retinol biology remaining obscure for so long is that retinoid and vitamin A applications have long produced confusing results. Topical retinoids are known to stimulate hair growth in wounds, but excessive retinoids have been shown to prevent hair cycling and cause alopecia; both positive and negative effects of retinoids on epidermal repair have been documented through various studies. The present study brings greater clarity by casting retinoids in a more central roleat the helm of regulating both hair follicle and epidermal stem cells.

By defining the minimal requirements needed to form mature hair cell types from stem cells outside the body, this work has the potential to transform the way we approach the study of hair biology, Tierney says.

How retinoids impact other tissues remains to be seen. When you eat a carrot, vitamin A gets stored in the liver as retinol where it is sent to various tissues, Fuchs says. Many tissues that receive retinol and convert it to retinoic acid need wound repair and use lineage plasticity, so it will be interesting to see how broad the implications of our findings in skin will be.

The Fuchs lab is also interested in how retinoids impact lineage plasticity in cancer, particularly squamous and basal cell carcinoma. Cancer stem cells never make the right choicethey are always doing something off-beat, Fuchs says. As we were studying this state in many types of stem cells, we began to realize that, when lineage plasticity goes unchecked, its a key contributor to cancer.

Basal cell carcinomas have relatively little lineage plasticity and are far less aggressive than squamous cell carcinomas. If future studies demonstrate that suppressing lineage plasticity is key to controlling tumor growth and improving outcomes, retinoids may have a key role to play in treating these cancers.

Its possible that suppressing lineage plasticity can improve prognoses, Fuchs says. This hasnt been on the radar until now. Its an exciting front to now investigate.

Reference: Vitamin A resolves lineage plasticity to orchestrate stem cell lineage choices by Matthew T. Tierney, Lisa Polak, Yihao Yang, Merve Deniz Abdusselamoglu, Inwha Baek, Katherine S. Stewart and Elaine Fuchs, 8 March 2024, Science. DOI: 10.1126/science.adi7342

Originally posted here:
Vitamin A's Puzzling Effects Unraveled: New Research Sheds Light on Stem Cell Repair Mechanisms - SciTechDaily

$343m investment to build stem-cell research center – BioProcess Insider – BioProcess Insider

Novo Nordisk Foundation will invest up to $343 million over a ten-year period to establish an international research center focused on stem cell medicine.

The center is a partnership entitled reNEW between the University of Copenhagen, Denmark, Murdoch Childrens Research Institute, Australia, and Leiden University Medical Center, The Netherlands.

The aim of the collaboration is to drive future stem cell-based treatments. The governing hub will be based at the Faculty of Health and Medical Sciences, University of Copenhagen and Melissa Little from the Murdoch Childrens Research Institute will serve as the CEO of the reNEW partnership, as well as being appointed executive director and professor of the center.

Image: Melissa Little, CEO of reNEW

reNEW builds international critical mass, expands the horizons and facilities available to all sites and enables the creation of international teams working towards targeted outcomes, Little told us.

She continued: Stem cell biology has come of age. The challenge now is to apply this understanding to outcomes that will benefit society whilst supporting these on research excellence.

Experts across the three institutions will work together to develop therapeutic options for patients with incurable diseases. According to the organization, the combination of exchange programs and joint technology platforms in the reNEW model will drive the partnership and train upcoming scientists in translational stem medicine.

My aim is to create an incentivized structure in which together the researchers can pivot to targeted product development and deliver these outcomes by creating more than the sum of the parts, Little said.

reNEW has separated the research into three themes, which includes the following:

reBUILD theme: This will focus on the use of stem cells to regenerate and/or recreate tissue once it has been damaged or destroyed. Programmes include stem cell-based therapies for diseases such as congenital heart disease, diabetes, ulcerative colitis and chronic renal disease, and Parkinsons disease.

reSOLVE theme: This sees the collaboration search for potential drug candidates using stem cell-based models of human tissue. This includes lab grown models of mini-organs to treat conditions like chronic ulceration and inherited kidney and heart disease.

reWRITE theme: This will use a combination of gene editing and stem cell technologies to produce treatment strategies for genetically inherited diseases. For example, immune deficiency disorders and progressive congenital muscle disorders.

My particular area of interest is kidney disease, said Little. While we are now able to recreate models of the human kidney from pluripotent stem cells, we wish to apply these to screen for treatments for inherited kidney disease and ultimately to bioengineer transplantable kidney tissue.

The $343 million funding will support 24 groups across the three sites together with advanced facilities available and accessible to researchers across the consortium.

Read more here:
$343m investment to build stem-cell research center - BioProcess Insider - BioProcess Insider

Cell Isolation/Cell Separation Market Growth, Development Factors, Business Insights, Value Chain and Sales … – Taiwan News

Introduction:

The global Cell Isolation/Cell Separation Market is on an unprecedented trajectory, projected to reach a staggering USD 17.3 billion by 2025, as reported by Report Ocean Market Research. This surge is underpinned by a myriad of factors, including the evolving landscape of medical research, the surge in stem cell isolation practices, and the increasing emphasis on personalized medicines. With North America currently dominating the market, closely followed by Europe and the Asia Pacific, the Cell Isolation/Cell Separation Market is witnessing a transformative phase with a focus on driving innovation for treating diseases like cancer.

Request To Download Free Sample of This Strategic Report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257

Market Dynamics:

For an in-depth analysis, you can refer sample copy of the report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257

Get a Free Sample PDF copy of the report @-https://reportocean.com/industry-verticals/sample-request?report_id=5257

Key Market Players:

Leading the charge in the Cell Isolation/Cell Separation Market are prominent players like Thermo Fisher Scientific, BD Biosciences, Beckman Coulter, Merck & Company, GE Healthcare, STEMCELL Technologies Inc., Terumo BCT, Bio-Rad Laboratories Inc., PluriSelect Life Sciences, Sigma-Aldrich Corporation, Clontech Laboratories, and Miltenyi BioTec. These companies are at the forefront of technological advancements, relentlessly pursuing breakthroughs in personalized medicine and cell research.

Conclusion:

As the Cell Isolation/Cell Separation Market hurtles toward a projected valuation of USD 17.3 billion by 2025, it stands as a testament to the remarkable strides in medical research and treatment methodologies. The convergence of technological innovation, a surge in stem cell practices, and the global shift towards personalized medicine are reshaping the landscape of healthcare. The markets dynamics, driven by research and development, government funding, and a growing interest in stem cell isolation, underscore its transformative potential.

The dominance of consumables, the varied techniques employed, and the focus on human cell isolation collectively paint a comprehensive picture of a market on the cusp of revolutionary breakthroughs. As North America retains its stronghold and the Asia Pacific emerges as a powerhouse, the global community is poised to witness pioneering advancements in precision medicine and disease treatment. The market players, with their unwavering commitment to innovation, are steering the Cell Isolation/Cell Separation Market toward a future where tailored medical solutions redefine the boundaries of possibility.

These responses will function a complete examination of the:

Access Full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=5257

Report Ocean is a renowned provider of market research reports, offering high-quality insights to clients in various industries. Their goal is to assist clients in achieving their top line and bottom line objectives, thereby enhancing their market share in todays competitive environment. As a trusted source for innovative market research reports, Report Ocean serves as a comprehensive solution for individuals, organizations, and industries seeking valuable market intelligence.

Email:sales@reportocean.com

Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, United States

Telephone: +1 888 212 3539 (US Toll-Free)

For more information and to explore their offerings, visit their website at:https://www.reportocean.com/

See original here:
Cell Isolation/Cell Separation Market Growth, Development Factors, Business Insights, Value Chain and Sales ... - Taiwan News

Stem Cell Science and Human Research Studies Ahead of Cargo Arrival – NASA Blogs

The seven-member Expedition 70 crew gathers for a dinner time portrait inside the International Space Stations Unity module. In the front row from left are, Flight Engineers Konstantin Borisov of Roscosmos, Jasmin Moghbeli of NASA, and Satoshi Furukawa from JAXA (Japan Aerospace Exploration Agency). In the back row are, Commander Andreas Mogensen from ESA (European Space Agency), NASA Flight Engineer Loral OHara, and Roscosmos Flight Engineers Oleg Kononenko and Nikolai Chub.

A cargo craft loaded with nearly three tons of food, fuel, and supplies is currently in orbit heading to the International Space Station, targeting early Saturday for docking. As the Expedition 70 crew members await the arrival of Progress 87, stem cell science, heart rate data collection and eye exam activities topped their research schedule on Thursday.

Progress 87 successfully launched from the Baikonur Cosmodrome in Kazakhstan at 10:25 p.m. EST Wednesday, Feb. 14. On Saturday, Feb. 17, the cargo craft will automatically dock to the aft port of the Zvezda service module at 1:12 a.m., with cosmonauts Oleg Kononenko and Nikolai Chub on duty to monitor the spacecrafts arrival.

Aboard station, four orbital residents spent most of the day on theMesenchymal Stem Cells in Microgravity Induced Bone Loss(MABL-A) investigation. MABL-Adelivered aboard Northrop Grummans20thCommercial Resupply Missionassesses the effects of microgravity on bone marrow stem cells.In the morning, NASA astronaut Loral OHara collected BioCell samples inside the habitat with assistance from JAXA (Japan Aerospace Exploration Agency) Flight Engineer Satoshi Furkawa. In the afternoon, NASA astronaut Jasmin Moghbeli took over the BioCell sampling work with assistance from ESA (European Space Agency) Commander Andreas Mogensen.

Mogensen also spent part of the day photographingPlant-Microbe Interactions in Space(APEX-10) petri platesanother investigation that launched aboard Northrop Grummans 20th resupply missionto examine whether beneficial microbes can mitigate some of the negative effects the space environment can have on plant growth and development.

In the afternoon, OHara conducted an array of activities for the CIPHER investigation, including the collection of heart rate data and completing an eye exam. CIPHER, or Complement of Integrated Protocols for Human Exploration Research, is an all-encompassing, total-body approach that examines how humans adapt tospaceflight.

In the Roscosmos segment, Chub worked with Flight Engineer Konstantin Borisov to film an educational video that demonstrates the capabilities of Roscosmos scientific hardware aboard station. Meanwhile, Kononenko conducted some routine maintenance in Zarya module. Near the end of the day, Borisov examined the Earths nighttime atmosphere in near-ultraviolet for an ongoing investigation aboard the orbital lab.

Learn more about station activities by following the space station blog, @space_station and @ISS_Research on X, as well as the ISS Facebook and ISS Instagram accounts.

Get weekly video highlights at: https://roundupreads.jsc.nasa.gov/videoupdate/

Get the latest from NASA delivered every week. Subscribe here: http://www.nasa.gov/subscribe

Read more here:
Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs

Space Station Astronauts Conduct Stem Cell Science and Human Research Ahead of Cargo Arrival – SciTechDaily

The suns last rays illuminate Earths atmosphere and refract in the camera lense in this photograph of an orbital sunset from the International Space Station as it soared 261 miles above the Pacific Ocean off the northern coast of Japan. Credit: NASA

A cargo craft loaded with nearly three tons of food, fuel, and supplies is currently in orbit heading to the International Space Station, targeting early Saturday for docking. As the Expedition 70 crew members await the arrival of Progress 87, stem cell science, heart rate data collection, and eye exam activities topped their research schedule on Thursday.

Progress 87 successfully launched from the Baikonur Cosmodrome in Kazakhstan at 10:25 p.m. EST Wednesday, February 14. On Saturday, February 17, the cargo craft will automatically dock to the aft port of the Zvezda service module at 1:12 a.m., with cosmonauts Oleg Kononenko and Nikolai Chub on duty to monitor the spacecrafts arrival.

NASA astronaut and Expedition 70 Flight Engineer Loral OHara treats brain cell-like samples inside the Kibo laboratory modules Life Science Glovebox aboard the International Space Station. She was processing the samples for the Cerebral Ageing space biology study that is exploring the degenerative processes of brain cells. Results may provide insights into accelerated aging symptoms seen in space and neurodegenerative diseases experienced on Earth. Credit: NASA

Aboard the station, four orbital residents spent most of the day on the Mesenchymal Stem Cells in Microgravity Induced Bone Loss(MABL-A) investigation. MABL-Adelivered aboard Northrop Grummans20thCommercial Resupply Missionassesses the effects of microgravity on bone marrow stem cells.In the morning, NASA astronaut Loral OHara collected BioCell samples inside the habitat with assistance from JAXA (Japan Aerospace Exploration Agency) Flight Engineer Satoshi Furkawa. In the afternoon, NASA astronaut Jasmin Moghbeli took over the BioCell sampling work with assistance from ESA (European Space Agency) Commander Andreas Mogensen.

Mogensen also spent part of the day photographingPlant-Microbe Interactions in Space(APEX-10) petri platesanother investigation that launched aboard Northrop Grummans 20th resupply missionto examine whether beneficial microbes can mitigate some of the negative effects the space environment can have on plant growth and development.

Astronauts headed to the International Space Station can now sign up for a broad suite of experiments that will help scientists pinpoint how the human body reacts to long-duration missions in space. The research will help NASA prepare astronauts for missions to the Moon, Mars, and beyond. Credit: NASA

In the afternoon, OHara conducted an array of activities for the CIPHER investigation, including the collection of heart rate data and completing an eye exam. CIPHER, or Complement of Integrated Protocols for Human Exploration Research, is an all-encompassing, total-body approach that examines how humans adapt tospaceflight.

In the Roscosmos segment, Chub worked with Flight Engineer Konstantin Borisov to film an educational video that demonstrates the capabilities of Roscosmos scientific hardware aboard the station. Meanwhile, Kononenko conducted some routine maintenance in the Zarya module. Near the end of the day, Borisov examined the Earths nighttime atmosphere in near-ultraviolet for an ongoing investigation aboard the orbital lab.

More:
Space Station Astronauts Conduct Stem Cell Science and Human Research Ahead of Cargo Arrival - SciTechDaily